Net Income (Annual) Chart

View Net Income (Annual) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Net Income (Annual) Chart
Start Trial

Historical Net Income (Annual) Data

View and export this data back to 1991. Start Trial.
Date Value
December 31, 2025 4.505B
December 31, 2024 4.413B
December 31, 2023 3.954B
December 31, 2022 4.338B
December 31, 2021 8.075B
December 31, 2020 3.513B
December 31, 2019 2.116B
December 31, 2018 2.444B
December 31, 2017 1.199B
December 31, 2016 895.52M
December 31, 2015 636.06M
December 31, 2014 348.07M
December 31, 2013 424.36M
December 31, 2012 750.27M
December 31, 2011 -221.76M
December 31, 2010 -104.47M
December 31, 2009 -67.83M
December 31, 2008 -82.71M
Date Value
December 31, 2007 -105.60M
December 31, 2006 -103.15M
December 31, 2005 -95.45M
December 31, 2004 41.70M
December 31, 2003 -107.46M
December 31, 2002 -124.38M
December 31, 2001 -76.18M
December 31, 2000 -21.65M
December 31, 1999 -23.07M
December 31, 1998 -8.625M
December 31, 1997 -11.58M
December 31, 1996 -32.42M
December 31, 1995 -23.51M
December 31, 1994 -30.65M
December 31, 1993 -39.88M
December 31, 1992 -19.11M
December 31, 1991 -4.468M

Net Income Definition

Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.

Read full definition.

Net Income (Annual) Range, Past 5 Years

View Net Income (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Net Income (Annual) Benchmarks

View Net Income (Annual) Benchmarks
Start Trial
Gilead Sciences, Inc. 8.51B
AbbVie, Inc. 4.193B
Alnylam Pharmaceuticals, Inc. 313.75M
Vertex Pharmaceuticals, Inc. 3.953B
Amgen, Inc. 7.711B